Author Archives: George Koroneos

GSK Scores High in Market Access

By George Koroneos | Published: June 23, 2010
GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity enhancement, [...]
Posted in Emerging Markets, Strategy | Tagged , , , , , , , | Leave a comment

Pharma and Cloud Computing: Are We There Yet?

By George Koroneos | Published: June 16, 2010
In the past few years, Microsoft has been working hard to create clinical trial platforms for the pharmaceutical industry. This year, the Redmond, WA-based behemoth has moved full-speed ahead with its virtual-server system, dubbed Azure. Microsoft is not only working on hosted applications, instead the company has established a massive online server or “cloud” that forms [...]
Posted in Technology | Tagged , , , , | 1 Comment

Industry and FDA Brace for Change

By George Koroneos | Published: June 16, 2010
While the convention floor of the 46th annual meeting of the Drug Information Association bustled with the usual vendors touting the latest and greatest clinical trial technology, the panels (particularly those that featured FDA members) had a remarkably somber tone. The main refrain was: “Things are going to change and everyone must step up or get [...]
Posted in Regulatory, Strategy | Tagged , , , , , , | 1 Comment

Hamburg Delivers DIA Keynote

By George Koroneos | Published: June 14, 2010
FDA Commissioner Margaret Hamburg delivered this year’s keynote speech in front of a packed room of pharma and bioscience personnel at the 46th annual meeting of the Drug Information Association, which opened Monday morning. Hamburg started her speech by explaining how her earliest goal as FDA chief was to build the field of regulatory [...]
Posted in Events, FDA | Tagged , , , | 2 Comments

Avastin Study Shows Promising Data for Cancer Patients

By George Koroneos | Published: June 8, 2010
Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American Society [...]
Posted in R&D | Tagged , , , , | Leave a comment